Published in Semin Radiat Oncol on April 01, 2011
Intravenously delivered graphene nanosheets and multiwalled carbon nanotubes induce site-specific Th2 inflammatory responses via the IL-33/ST2 axis. Int J Nanomedicine (2013) 0.97
Nanoparticles for imaging: top or flop? Radiology (2014) 0.97
Advances and future of Radiation Oncology. Rep Pract Oncol Radiother (2013) 0.95
Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles. Int J Nanomedicine (2013) 0.92
Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells. Mol Pharm (2012) 0.89
Can nanotechnology potentiate photodynamic therapy? Nanotechnol Rev (2012) 0.89
Near-infrared quantum dots for HER2 localization and imaging of cancer cells. Int J Nanomedicine (2014) 0.87
Assessing the barriers to image-guided drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.86
Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer. Bioimpacts (2014) 0.85
Shining light on nanotechnology to help repair and regeneration. Biotechnol Adv (2012) 0.82
Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm. Eur Radiol (2015) 0.82
Dawn of advanced molecular medicine: nanotechnological advancements in cancer imaging and therapy. Crit Rev Oncog (2014) 0.81
Applications of nanoparticles for diagnosis and therapy of cancer. Br J Radiol (2015) 0.81
Nanoparticles and radiotracers: advances toward radionanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.79
Immunotoxicological impact of engineered nanomaterial exposure: mechanisms of immune cell modulation. Toxicol Mech Methods (2013) 0.78
Uveal melanoma: relatively rare but deadly cancer. Eye (Lond) (2016) 0.75
Advances in the clinical translation of nanotechnology. Curr Opin Biotechnol (2017) 0.75
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Renal clearance of quantum dots. Nat Biotechnol (2007) 12.54
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med (2003) 9.09
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A (2008) 7.06
Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med (2006) 7.05
Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood (2004) 4.66
Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma. Eur Respir J (2009) 4.54
High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem (1999) 4.41
Gold nanoparticles for biology and medicine. Angew Chem Int Ed Engl (2010) 4.14
Magnetic relaxation switches capable of sensing molecular interactions. Nat Biotechnol (2002) 4.13
Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J Am Chem Soc (2005) 4.02
Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation (2007) 3.85
Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology (1990) 3.50
Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev (2010) 3.30
Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem (2006) 2.91
A synthetic DNA walker for molecular transport. J Am Chem Soc (2004) 2.89
An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater (2006) 2.84
Inhaled carbon nanotubes reach the subpleural tissue in mice. Nat Nanotechnol (2009) 2.78
Nano-flares: probes for transfection and mRNA detection in living cells. J Am Chem Soc (2007) 2.67
Intrinsic peroxidase-like activity of ferromagnetic nanoparticles. Nat Nanotechnol (2007) 2.61
Tumor therapy with targeted atomic nanogenerators. Science (2001) 2.48
Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug Chem (2002) 2.45
Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release (2001) 2.44
NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials (2009) 2.40
Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett (2009) 2.37
Inhaled multiwalled carbon nanotubes potentiate airway fibrosis in murine allergic asthma. Am J Respir Cell Mol Biol (2008) 2.32
Sheddable coatings for long-circulating nanoparticles. Pharm Res (2007) 2.15
In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res (2003) 2.12
Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol (2002) 2.06
Superparamagnetic gadonanotubes are high-performance MRI contrast agents. Chem Commun (Camb) (2005) 2.05
Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett (2009) 1.97
Theranostic nanomedicine for cancer. Nanomedicine (Lond) (2008) 1.96
Induction of mesothelioma by a single intrascrotal administration of multi-wall carbon nanotube in intact male Fischer 344 rats. J Toxicol Sci (2009) 1.75
In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci (2005) 1.72
Nanoparticle imaging of integrins on tumor cells. Neoplasia (2006) 1.70
Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol (2009) 1.67
Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small (2009) 1.64
Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications. Basic Res Cardiol (2008) 1.60
Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci (1995) 1.58
Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci U S A (2010) 1.54
Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles. Bioconjug Chem (2010) 1.52
Metabolic biotinylation of cell surface receptors for in vivo imaging. Nat Methods (2006) 1.50
Gd(III)-nanodiamond conjugates for MRI contrast enhancement. Nano Lett (2010) 1.50
Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. Acad Radiol (2002) 1.47
Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med (2010) 1.36
Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol (2010) 1.35
Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nat Rev Clin Oncol (2010) 1.30
Novel nanosensors for rapid analysis of telomerase activity. Cancer Res (2004) 1.20
The role of nanotoxicology in realizing the 'helping without harm' paradigm of nanomedicine: lessons from studies of pulmonary effects of single-walled carbon nanotubes. J Intern Med (2010) 1.19
Liposomes as delivery systems for antibiotics. Int J Pharm (2009) 1.15
Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest (2009) 1.10
Sensitive, noninvasive detection of lymph node metastases. PLoS Med (2004) 1.07
[Cell tracking. Principles and applications]. Radiologe (2007) 0.98
Long-term hepatotoxicity of polyethylene-glycol functionalized multi-walled carbon nanotubes in mice. Nanotechnology (2010) 0.93
Challenging nature's monopoly on the creation of well-defined nanoparticles. Nanomedicine (Lond) (2010) 0.92
Targeted nanomaterials for radiotherapy. Nanomedicine (Lond) (2007) 0.92
AuNP-DG: deoxyglucose-labeled gold nanoparticles as X-ray computed tomography contrast agents for cancer imaging. Mol Imaging Biol (2010) 0.90
Liposomal formulation of retinoids designed for enzyme triggered release. J Med Chem (2010) 0.88
Gold nanoparticles functionalized by gadolinium-DTPA conjugate of cysteine as a multimodal bioimaging agent. Bioorg Med Chem Lett (2010) 0.84
Stable containment of radionuclides on the nanoscale by cut single-wall carbon nanotubes. J Phys Chem B (2005) 0.83
A rotational DNA nanomotor driven by an externally controlled electric field. Small (2010) 0.79
Semiconductor quantum dots: synthesis and water-solubilization for biomedical applications. Expert Opin Biol Ther (2008) 0.78
Characterization of ultrasmall magnetite [correction of paramagnetic magnetite] particles as superparamagnetic contrast agents in MRI. Invest Radiol (2000) 0.76
Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med (2007) 3.08
Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev (2007) 2.60
Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med (2013) 2.03
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
Targeted alpha particle immunotherapy for myeloid leukemia. Blood (2002) 1.99
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol (2006) 1.98
Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res (2008) 1.98
Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res (2010) 1.80
Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci U S A (2010) 1.54
Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica (2005) 1.50
PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. PLoS One (2007) 1.43
The promise of targeted {alpha}-particle therapy. J Nucl Med (2005) 1.43
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood (2010) 1.41
Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res (2004) 1.38
Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery. Nat Nanotechnol (2013) 1.35
Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res (2003) 1.31
Design and synthesis of 225Ac radioimmunopharmaceuticals. Appl Radiat Isot (2002) 1.26
Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res (2007) 1.23
A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res (2010) 1.22
Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. J Clin Invest (2004) 1.21
Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev (2008) 1.20
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother (2010) 1.20
High-throughput identification of inhibitors of human mitochondrial peptide deformylase. J Biomol Screen (2007) 1.18
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res (2010) 1.17
Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int J Nanomedicine (2010) 1.12
Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of γ-secretase. J Biol Chem (2012) 1.10
Synthesis and biodistribution of oligonucleotide-functionalized, tumor-targetable carbon nanotubes. Nano Lett (2008) 1.09
Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS One (2007) 1.08
A new human peptide deformylase inhibitable by actinonin. Biochem Biophys Res Commun (2003) 1.07
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood (2003) 1.07
Efforts to control the errant products of a targeted in vivo generator. Cancer Res (2005) 1.06
Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med (2004) 1.06
Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters. J Am Soc Nephrol (2005) 1.05
Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens. ACS Nano (2011) 1.04
Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys (2006) 1.02
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol (2003) 0.99
Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. J Natl Cancer Inst (2010) 0.98
Engineered liposomes for potential alpha-particle therapy of metastatic cancer. J Nucl Med (2004) 0.97
A high-throughput screen for alpha particle radiation protectants. Assay Drug Dev Technol (2010) 0.95
Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood (2004) 0.95
Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules. Leuk Res (2006) 0.94
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer (2009) 0.93
Targeted nanomaterials for radiotherapy. Nanomedicine (Lond) (2007) 0.92
Alpha particles induce apoptosis through the sphingomyelin pathway. Radiat Res (2011) 0.91
Inhibition of human peptide deformylase disrupts mitochondrial function. Mol Cell Biol (2010) 0.91
Structure and activity of human mitochondrial peptide deformylase, a novel cancer target. J Mol Biol (2009) 0.91
Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. J Clin Invest (2007) 0.90
Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin Cancer Res (2004) 0.89
A high-throughput scintillation proximity-based assay for human DNA ligase IV. Assay Drug Dev Technol (2011) 0.88
Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells. PLoS One (2009) 0.88
Toward a prostate specific antigen-based prostate cancer diagnostic assay: preparation of keyhole limpet hemocyanin-conjugated normal and transformed prostate specific antigen fragments. J Am Chem Soc (2008) 0.87
Radioimmunotherapy for acute leukemia. Cancer Control (2002) 0.86
Non-natural and photo-reactive amino acids as biochemical probes of immune function. PLoS One (2008) 0.85
Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. Blood (2012) 0.85
Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers. Bioconjug Chem (2007) 0.85
A self-assembling short oligonucleotide duplex suitable for pretargeting. Nucleic Acid Ther (2013) 0.84
Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. J Leukoc Biol (2004) 0.84
Immunotoxin resistance in multidrug resistant cells. Cancer Res (2003) 0.83
Immunotherapeutic approaches for hematologic malignancies. Hematology Am Soc Hematol Educ Program (2004) 0.83
Deploying RNA and DNA with Functionalized Carbon Nanotubes. J Phys Chem C Nanomater Interfaces (2013) 0.83
Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators. Bioconjug Chem (2006) 0.83
Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia. Semin Hematol (2003) 0.82
Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood (2002) 0.81
Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens. Clin Cancer Res (2005) 0.81
CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res (2005) 0.80
Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. Biol Blood Marrow Transplant (2003) 0.80
Approaching untargetable tumor-associated antigens with antibodies. Oncoimmunology (2013) 0.80
Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase. Bioorg Med Chem Lett (2011) 0.79
Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. Blood (2005) 0.79
Dysregulation of IRP1-mediated iron metabolism causes gamma ray-specific radioresistance in leukemia cells. PLoS One (2012) 0.79
Therapeutic antibodies to intracellular targets in cancer therapy. Expert Opin Biol Ther (2013) 0.79
Peptide vaccines for myeloid leukaemias. Best Pract Res Clin Haematol (2008) 0.79
Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer. J Liposome Res (2010) 0.78
A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer (2002) 0.77
Meeting report: drug carriers in medicine and biology. Mol Pharm (2009) 0.75
A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. J Clin Invest (2017) 0.75
Immune therapy of chronic myelogenous leukemia. Leuk Res (2005) 0.75
Reaching un-drugable intracellular targets with the long arm of antibodies. Oncotarget (2013) 0.75
Immunoreactivity assay for alpha-particle emitting monoclonal antibody constructs. Appl Radiat Isot (2005) 0.75